Avantor (AVTR) is back in focus after announcing an expanded collaboration between its NuSil brand and the Population Council to support development of a three-month dapivirine vaginal ring for HIV prevention.

The collaboration news comes at a time when Avantor’s recent momentum has picked up, with a 30 day share price return of 14.72% and a 90 day share price return of 32.73%. However, the 1 year total shareholder return is still down 15.59%, which points to improving sentiment from a previously depressed base.

If this kind of health focused partnership has your attention, it may be a useful moment to see what else is on the move in 39 healthcare AI stocks

After a sharp 90 day rebound but a one year record that is still in the red, Avantor now sits in an awkward middle ground. Is this the moment to commit fresh capital, or is it better to wait for a cleaner entry point as the valuation picture unfolds?

Most Popular Narrative: 6.6% Overvalued

On the most followed narrative, Avantor’s fair value of $10.31 sits slightly below the last close at $10.99, framing a tight but important valuation gap.

The analysts have a consensus price target of $10.31 for Avantor based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $7.0.

Want to see what sits behind that fair value for Avantor? The narrative leans on a sharp earnings swing, modest revenue progress, and a future profit multiple that needs real delivery.

Result: Fair Value of $10.31 (OVERVALUED)

However, Avantor still faces pressure from aggressive price competition and bioprocessing weakness. This could restrain margins and call the current fair value into question.

Another View: What Avantor’s P/S Ratio Is Telling You

While the most followed Avantor narrative flags a 6.6% premium to its fair value, a simple sales based lens paints a different picture. Avantor trades on a P/S of 1.1x versus 4.1x for the US Life Sciences industry and 6.1x for peers, with a fair ratio estimate of 2.9x.

That gap suggests the market is pricing in meaningful execution and balance sheet risk, even as revenue forecasts point to modest growth and a path back to profitability. For you, the key question is whether this discount looks like caution that proves justified, or patience that eventually gets rewarded.

Next Steps

If this mix of cautious and optimistic signals around Avantor leaves you undecided, it is worth acting promptly by checking both sides of the story through 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Avantor?

If Avantor has you thinking more broadly about opportunities, do not sit on the sidelines. Use these focused screens to quickly surface stocks that fit your style.

• Target potential bargains trading below their estimated worth by reviewing the 45 high quality undervalued stocks.
• Strengthen your watchlist with companies that pair financial resilience with sound fundamentals through the solid balance sheet and fundamentals stocks screener (48 results).
• Spot early stage opportunities with stronger financial profiles than typical micro caps by scanning the 20 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.